Abstract
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have